5328152025-04-012025-06-305328152025-06-305328152025-04-012025-06-30in-capmkt:OtherExpenses1Member5328152025-04-012025-06-30in-capmkt:OtherExpenses2Member5328152025-04-012025-06-30AuditorDomain15328152025-06-30Statement15328152025-04-012025-06-30Statement15328152025-06-30StatementDynamic1I1Statement15328152025-06-30StatementDynamic1I2Statement15328152025-06-30StatementDynamic1I3Statement1iso4217:INRxbrli:pureiso4217:INRxbrli:shares532815SMSPHARMANOTLISTEDINE812G01025SMS PHARMACEUTICALS LIMITEDMain BoardEquity2025-04-012026-03-312025-08-092025-08-02INRLakhsQuarterlyFirst quarterSingle segmentManufacture of Active Pharmaceutical Ingredients(Bulk Drugs), Peptides and Intermediates2025-08-0909:15:002025-08-0911:45:00Declaration of unmodified opiniontrue1falseNot Applicable2025-04-012025-06-30UnauditedStandalone19604710005931000196640200014728910000-3568830001818490005840400097525000273998000172778400023861800002386180005000000065430005654300001820750000000182075000-9440001811310008865200012.052.05002.052.051 The above standalone financial results have been reviewed by the Audit Committee and has been approved by the Board of Directors at its meeting held on August 09, 2025. The Statutory Auditors have issued an un-modified conclusion report on the financial results. <BR> <BR> 2 These standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act,2013 (the Act) read with relevant rules issued thereunder and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India (SEBI). <BR> <BR> 3 The Company is engaged in the manufacturing of Active Pharmaceutical Ingredients and their intermediates and the same constitutes a single reportable business segment as per Ind AS108. <BR> <BR> 4Financial results for the quarter ended 31.03.2025 are the balancing figures between audited figures in respect of full financial year and the unaudited published year to date figures up to the third quarter of the respective financial year, which were subjected to limited review by the statutory auditors. The figures have been regrouped/reclassified as necessary. <BR> Manufacturing Expenses197272000Other Expenses767260009440000-944000UnauditedtrueM/s.Suryanarayana & Suresh, Chartered Accountantstrue2026-07-31Preferential Issues2024-03-1911430000002025-06-30trueCARE Ratings LimitedfalseNILNILNILLakshmi Narayana TammineediChief Financial OfficerHyderabad2025-08-09Capital Expenditure: Expansion of production capacities in phased manner and installation of additional utility equipments as well as recovery systems. Proposed to start backward integration of Key Starting Materials (KSM) for existing as well as new products under pipeline at R&D by setting up new production blocks.NA62870000001714000000The Total issue size is Rs. 11430 (in lakhs). <br></br> <br></br> 1. The company has received Rs. 2857 (in lakhs) on 19.03.2024 as 25% upfront payment and allotted 90,00,000 warrants. <br></br> <br></br> 2. On 27.03.2025, 40,00,000 warrants has been converted into equity shares on receipt of balance 75% amount i.e. Rs. 3810 (in lakhs).Working Capital: Expanding the production capacities, backward integration of KSM, which led to an increased requirement of Working Capital, operational expenditure and other related expenses.NA40000000004953000000During the quarter an amount of Rs.3810 lakhs has been utilized for temporary deployment of working capital against the pending utilization in line with the objects of the issue.General Corporate Purposes: which includes, inter alia, meeting ongoing general corporate exigencies and contingencies, expenses of the Company as applicable in such a manner and proportion as may be decided by the Board from time to time, and/or any other general purposes as may be permissible under applicable lawsNA11430000006667000000